KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Daily Values

Growth Metrics

Others

Regeneron Pharmaceuticals (REGN) Notes Payables (2020)

Historic Notes Payables for Regeneron Pharmaceuticals (REGN) over the last 3 years, with Q2 2020 value amounting to $1.5 billion.

Regeneron Pharmaceuticals' Notes Payables changed N/A to $1.5 billion in Q2 2020 from the same period last year, while for Jun 2020 it was $1.5 billion, marking a year-over-year change of. This contributed to the annual value of $1.6 million for FY2015, which is 7866.67% down from last year.
Latest data reveals that Regeneron Pharmaceuticals reported Notes Payables of $1.5 billion as of Q2 2020.
In the past 5 years, Regeneron Pharmaceuticals' Notes Payables registered a high of $1.5 billion during Q2 2020, and its lowest value of $1.5 billion during Q2 2020.